SOLAR-PROMOTION
15.5.2024 15:14:34 CEST | Business Wire | Press release
Climate-neutral power generation from solar and wind will place several new challenges on the energy system. Key is that a significantly higher degree of flexibility will be required compared to today to keep supply and consumption in balance. Flexible consumers can make a significant contribution to this. How this can be achieved will be an important topic at EM-Power Europe, the international trade fair for energy management and integrated energy solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515343343/en/
EM-Power Europe 2024 presents a wide range of solutions for more digitalization and flexibility. (Photo: Solar Promotion GmbH)
"According to EU calculations, the demand for flexibility will increase by 133 percent between now and 2030," explains Michael Villa, Managing Director of the European industry association smartEn. In a recent study, Agora Energiewende came to the conclusion that by 2035, electric cars, heat pumps and home storage systems will be able to shift around ten percent of the annual electricity demand required in Germany. That would accumulate to around 100 terawatt hours. This flexibility on the consumer side will save the economy around 4.8 billion euros. But how can consumers make contributions to the energy transition?
Making ideal use of your own electricity
An initial consumer contribution to flexibilization has been a proven state of the art for years: prosumers with their own photovoltaic system linked to a stationary battery storage system, their own heat pump and charge their electric car with the electricity they generate themselves. This way, they not only minimize their own electricity consumption from the grid - they also reduce the load on the respective distribution grid by maximizing their own consumption.
Supply and demand
When there is a lot of electricity available from the sun and wind, prices on the European trading platform EEX fall. From 2025, all electricity suppliers in Germany will be obliged to offer their customers dynamic tariffs. They will then be able to optimize their consumption in terms of price. However, if many households consume a lot of electricity at the same time, the distribution grids will be under considerable strain. Making grid charges more flexible could counteract this effect: from 2025, grid charges in Germany will be higher at times of high grid utilization and lower at times of low utilization.
Suppliers intervene
Suppliers will also contribute to flexibility to a greater extent: if grid capacity threatens to become scarce, they can reduce their customers' consumption. This is an example that has been successfully practiced: If a bottleneck becomes apparent, suppliers can temporarily switch off connected heat pumps themselves. However, customers do not suffer any loss of comfort as a result, as thermal storage units keep their homes warm. In return, they receive the electricity for their heat pump at a particularly favorable price.
New: throttling instead of switching off
A novelty to the Energy Industry Act (EnWG) allows grid operators to throttle some wallboxes and heat pumps if there is a risk of grid overload. In return, grid operators may no longer refuse to connect such consumers on the grounds of possible grid overload.
EM-Power Europe
EM-Power Europe is the international trade fair for energy management and integrated energy solutions. Under the motto "Empowering Grids and Prosumers", it brings together stakeholders and focuses on current trends and developments. EM-Power Europe will take place from June 19 to 21, 2024 at Messe München.
Further information: www.em-power.eu
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515343343/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
